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1. Introduction  
Human embryonic stem cells (hESCs) were first established as an in vitro culture system 
(Thomson et al., 1998). hESCs are pluripotent cells that are able to self-renew and can 
differentiate into the three primary germ layers: endoderm, ectoderm and mesoderm. 
Specifically, hESCs can be used to generate gut epithelium, cartilage, bone, muscle, 
neuroepithelium, and embryonic ganglia (Zhang et al., 2001, Itskovitz-Eldor et al., 2000, 
Sottile et al., 2003, Thomson et al., 1998, Green et al., 2003). Since these hESC cell lines can be 
maintained for months in an undifferentiated state, they can be used as a stable resource to 
model human development in vitro. The conversion of hESCs to neural progenitors and 
subsequently to the three main neural lineages: neurons, astrocytes and oligodendrocytes 
was first demonstrated in 2001 (Reubinoff et al., 2001).   
The recent advent (Takahashi and Yamanaka, 2006) of induced pluripotent stem cells 
(iPSCs) makes it possible to derive pluripotent stem cells from somatic tissue. iPSCs are 
derived by transfecting somatic cells (e.g. skin fibroblasts) with a select group of 
transcription factors; Sox2, Oct4, Myc and Klf4 to induce reprogramming of the genome 
over a period of 3-4 weeks. This breakthrough by Yamanaka and colleagues enables the 
modelling of human disease by, for example, taking a patient’s skin cells, converting them 
to iPSCs and then differentiating it to any desired cell-type. Thus iPSC technology opens a 
new era of patient-specific disease modelling. Here, we review diseases of the nervous 
system that have been modelled using iPSC which includes; RETT syndrome (RTT), Familial 
dysautonomia (FD), Parkinson’s disease (PD), Huntingtons (HD) and Amyotrophic Lateral 
Sclerosis (ALS). To provide some background to the neurological disease modelling studies 
by iPSCs we begin by reviewing protocols for neural induction (differentiation) of hESC.   
2. Neural induction and neuronal differentiation of human embryonic stem 
cells (hESCs) 
2.1 Neural induction of human ESCs 
Several protocols, based on knowledge from developmental studies of embryogenesis and 
neurogenesis, have been developed to optimize yield and purity of neural progenitors from 
hESCs (Fig1). They can be categorized into two broad approaches. The first involves a 
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stepwise change of culture medium components followed by expansion of neural 
progenitors (Reubinoff et al., 2001). This protocol involves the long-term culture (3 weeks) of 
hESCs without replenishing the mouse embryonic fibroblast layer. These cells rapidly 
undergo morphological changes, forming neural rosettes. They are subsequently dissociated 
and replated in medium permissive for the growth and maintenance of NSCs (DMEM/F12, 
B27 supplement, EGF [epidermal growth factor], bFGF [basic fibroblast growth factor]). 
Similar to mouse ESCs, hESCs can also be differentiated as suspension cultures where they 
form cystic embryoid bodies (EBs).  Formation of these three-dimensional spheres can 
recapitulate the microenvironment during embryo development, and are preferred over 
monolayer formats because it allows for up-scaling of differentiation cultures to a greater 
extent. However, differentiation of hESCs in this sphere format gives rise to issues such as 
heterogeneity (containing cell types pertaining to the three germ layers) and differential 
access to soluble factors, which translates to difficulties in optimizing the purity of the 
desired differentiated progenitors. 
The second approach to induce neural lineage cells, is to co-culture hESCs with a variety of 
stromal cell types, such as the PA6 and MS5 (Kawasaki et al., 2000, Hong et al., 2008, 
Chimge and Bayarsaihan, 2010). Both PA6 and MS5 stromal cells  were derived from murine 
bone marrow. This induction method is based on the knowledge that signals from 
mesodermal cells of the Spemann organizer (which develop into the notochord) can induce 
overlying ectoderm to neuroectodermal fate (Harland and Gerhart, 1997, Londin et al., 
2005). This neural induction protocol was reported to generate up to 92% NCAM [neural cell 
adhesion molecule]–positive cells in 12 days. Given the ease and efficiency of this protocol it 
is not surprising that it is widely used. However, the neural-inducing effect of the stromal 
cells is not fully understood. PA6 cells can induce neural differentiation of hESCs in the 
absence of physical contact, but the conditioned medium of PA6 cells was unable to induce 
neural differentiation (Kawasaki et al., 2000). In addition, paraformalydehye-treated PA6 
cells continued to exhibit neural-inducing activity, suggesting that the viability of these cells 
is not vital. In order to fine-tune the procedure to exclude animal products, a matrix material 
from the human amniotic membrane was found to support neural induction of hESCs with 
similar efficiencies to that of the mouse stromal cells (Ueno et al., 2006). 
Given the caveats in the EB and co-culture methods, strategies were developed to maximize 
the induction of hESCs into neural lineage, using differentiating factors and monolayer 
subculture systems. The secretion of the bone morphogenic protein (BMP) antagonists,  
noggin and chordin, from the epidermal ectoderm of the Xenopus embryo was demonstrated 
to be essential for neural induction (Sasai et al., 1996). In addition, follistatin, an inhibitor of 
Activin signaling, was found to promote neural induction (Hemmati-Brivanlou and Melton, 
1994). Hence, strategies used for increasing the yield of neural derivatives from hESCs 
include using inhibitors of BMP signaling such as Noggin (Itsykson et al., 2005), and the 
inhibitors of Activin/Nodal signaling such as the pharmacological inhibitor of Nodal 
signaling, SB431542 (Smith et al., 2008). Since both signaling pathways converge to 
downstream SMAD proteins, subsequent work further optimized the induction of neural 
lineage cells by using the inhibitors of both BMP and Nodal signaling (Chambers et al., 
2009). However, Noggin, as a protein is expensive and may exhibit batch-to-batch 
variability. Recent findings report that substituting noggin with a small-molecule inhibitor 
of BMP, Dorsomorphin, can efficiently promote neural differentiation of hESCs and iPSCs 
(Morizane et al., 2010, Zhou et al., 2010). Other methods rely on genetic manipulations such 
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as generating nestin-EGFP hESC reporter lines  to allow purification of hESC-derived neural 
progenitors (Noisa et al., 2010).  
 
 
Fig. 1. Schematic representation of neural induction and patterning in in vivo and in vitro. 1) 
At early gastrulation, the notochord (orange) secretes BMP-antagonists, such as Noggin and 
Chordin to create a gradient of BMP activity (yellow).   2) Neuroepithelial (NE) cells that are 
proximal to the notochord become neural precursors (grey) as a consequence of low BMP 
activity; and the rest of the ectoderm becomes epithelial (yellow) or neural crest (not 
shown). The NE is patterned by many signals including Shh, RA, Noggin and Chordin 
(orange) that are secreted from the notochord; BMP (yellow) from the epithelium and FGF 
(blue) from the somites. 3) The cells in the NE differentiate to specific subtypes of neurons 
depending on the location in the neural tube and the factors that influence the 
differentiation.  Neural induction and patterning of human ESCs can be induced in vitro as 
shown in the right panels (bright field micrograph or GFP labeled neuronal sub type). 
The next aim, upon obtaining neural progenitors/stem cells, is to coax these cells into 
differentiation of various neuronal subtypes including the cholinergic neurons, 
dopaminergic neurons, motorneurons, and peripheral sensory neurons. Several  methods 
using various combination of protein factors, co-culture systems and small molecules 
have successfully been utilized to obtain  individual neuronal subtypes. The basic strategy 
for developing culture cocktails to obtain neuronal subtypes is to mimic signals from early 
developmental events during specification of the body axis of the embryo. Factors 
frequently used to induce neural progenitor differentiation include retinoic acid (RA), 
FGFs and Wingless-Int (Wnts) that can poise cells to differentiate to the neural lineage 
along the the anterior/posterior (A-P) axis (Hendrickx et al., 2009, Onai et al., 2009). 
Similarly, Sonic Hedgehog (Shh) and BMPs secreted from the ventral and dorsal neural 
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tube respectively are important for the precise patterning of multiple neuronal 
progenitors (Furuta et al., 1997, Litingtung and Chiang, 2000). Hence, the efficiency of 
deriving specific neuronal subtypes can be influenced by the mode of neural induction. 
The selection of the appropriate neural differentiation protocol is pertinent for the 
maximization of desired neuronal subtype. 
2.2 Neuronal differentiation of human ESCs 
Many neuronal subtypes have successfully been derived from hESCs (Fig1). Amongst them 
are the dopaminergic neurons, serotonergic neurons, peripheral sensory neurons, and 
cholinergic neurons (Bissonnette et al., 2011). Dopaminergic neurons are progressively lost 
in Parkinson’s disease (PD), while the motorneurons are lost in amyotrophic lateral sclerosis 
(ALS). The factors and conditions used for successful derivation of dopaminegic neurons, 
motoneurons as well as other neuronal subtypes can be found in Table 1.  
Shh and FGF8 were identified to be crucial for the specification of dopaminergic neurons in 
vivo (Ye et al., 1998) but were not directly effective in vitro (Stull and Iacovitti, 2001). This led 
to the search for other signals in promoting dopaminergic neuron differentiation. Currently, 
differentiation of human ESCs into midbrain dopaminergic neurons can be achieved 
through the formation of EBs and the use of various factors such as serum-free conditioned-
medium from human hepatocarcinoma cell line HepG2, brain-derived neurotrophic factor 
(BDNF), ascorbic acid, transforming growth factor (TGF), and glial cell line-derived  
Neurotrophic factor (GDNF)  (Cho et al., 2008a, Cho et al., 2008b, Park et al., 2004, Schulz et 
al., 2004, Yan et al., 2001). Particularly, TGFß can cooperate with Shh and FGF8 to increase 
the yield of dopaminergic neurons by enhancing their survival (Roussa et al., 2004); and 
GDNF was found to be important for the maintenance of motoneurons in the striatum 
proper (Nevalainen et al., 2010). Large-scale production of dopaminergic neurons from 
hESC was reported using the EB format with addition of Shh, FGF8 and ascorbic acid. 86% 
of totally differntiated cells were dopaminergic neurons. Secretion of factors by PA6 cells is 
important for dopaminergic differentiation (Vazin et al., 2008). PA6 secreted factors include 
stromal cell-derived factor 1 (SDF-1/CXCL12), pleiotrophin (PTN), insulin-like growth 
factor 2 (IGF2), and ephrin B1 (EFNB1). 
The protocols used for the specification of spinal motoneurons from hESCs were derived from 
developmental studies. Here motoneurons were found to be induced by signals such as 
retionic acid from the caudal paraxial mesoderm (Guidato et al., 2003). Shh signaling from the 
notochord is also required for the induction of motoneurons (Lewis and Eisen, 2001). Neural 
induction is predominantly performed through the formation of EBs, using defined medium 
conditions. Because neuroectodermal cells differentiated from hESCs generally have a rostral 
character, motoneuron differentiation is then achieved by the caudalizing factor retinoic acid 
followed by the ventralizing factor Shh (Li et al., 2005). Small molecules that can activate the 
Shh signaling, purmorphamine and SAG (a chlorobenzothiophene-containing Hh pathway 
agonist), have been shown to be effective as substitutes of Shh in motoneuron differentiation 
(Li et al., 2008, Hu and Zhang, 2009, Wada et al., 2009). The use of Hb9 (homeobox gene 
selectively expressed in motoneurons)  promoter driven GFP hESCs allows isolation of a fairly 
pure population of motoneurons (Singh Roy et al., 2005). Enrichment of derived motoneurons, 
up to 80%, was also shown to be achieved by gradient centrifugation in Biocoll (Wada et al., 
2009), alleviating the need for genetic manipulations. 
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Neuronal 
Subtypes 
Neural Induction Method 
Factors for Final 
Differentiation 
Done 
with 
iPS? 
Reference 
Dopaminergic 
neurons 
50%-
MedIIconditionedmedium, 
bFGF or DMEM/N2 
DMEM/N2, GDNF, 
BDNF, 5% serum 
 
(Schulz et al., 
2004) 
EB with RA and bFGF BDNF, TGF-α  (Park et al., 
2004) 
EB, followed by bFGF and 
N2 supplement 
Shh, FGF8  
(Cho et al., 
2008) 
PA6 co-culture PA6, Shh, FGF8, GDNF  
(Vazin et al., 
2008) 
PA6 co-culture 
PA6 co-culture or  
SDF-1/CXCL12, PTN, 
IGF2, EFNB1 
 
(Vazin et al., 
2009) 
MS5 co-culture RA, Shh, FGF8, Wnt1 √ (Cooper et 
al., 2010) 
Motoneurons 
EB, then adherent in  
F12/DMEM, N2 
supplement, heparin and 
bFGF 
RA, then Shh  
(Li et al., 
2005) 
 EB, bFGF 
RA in DMEM/F12,N2, 
heparin, cAMP. Then 
Shh/purmorphamine, 
then GDNF, BDNF, 
IGF1 
 
(Li et al., 
2008) 
 EB 
RA, then 
Shh/purmophamine, 
then BDNF, GDNF, 
IGF, cAMP 
√ (Hu and 
Zhang, 2009) 
Peripheral 
sensory 
neurons 
PA6 co-culture 
Co-culture with PA6 
stromal cells 
 
(Pomp et al., 
2008) 
MS-5 co-culture, followed 
by  Shh, FGF8, BDNF, 
ascorbic acid 
BDNF, GDNF, NGF 
(nerve growth factor), 
Dibutyryl-cAMP 
√ (Lee et al., 
2009) 
Cholinergic 
neurons 
Free-floating aggregates 
BDNF, NT3, CNTF, 
NGF 
 
(Nilbratt et 
al., 2010) 
 
RA, followed by free-
floating aggregates 
FGF8, Shh, BMP9  
(Bissonnette 
et al., 2011) 
Serotonergic 
neurons 
RA with EB formation 
5-HT, forskolin, acidic 
FGF, BDNF, GDNF 
 
(Kumar et al., 
2009) 
Table 1. Factors used in differentiation of hESC-induced NSCs into the various neuronal 
subtypes.  
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2.3 Glial differentiation of hESCs 
The two glial cell types of the nervous system, the astrocytes and oligodendrocytes, play 
supporting roles in the brain and peripheral nervous system. Astrocytes secrete various 
neurotrophic factors, are known to modulate oligodendrocyte myelination of neuronal 
axons (Moore et al., 2011), and modulate neurotransmitter levels through re-uptake and 
release mechanisms (Voutsinos-Porche et al., 2003). Evidence is emerging that implicates 
astrocytes in the pathogenesis of neurological disorders such as Rett syndrome (Maezawa et 
al., 2009) and ALS (Nagai et al., 2007). A protocol to obtain astrocytes includes exposure of 
adherent hESCs to cyclopamine, an inhibitor of hedgehog signaling, and subsequent culture 
in human astrocyte medium to generate a high percentage of nestin and glial fibrillary 
acidic protein (GFAP)-expressing cells (Lee et al., 2006).  
Oligodendrocytes are cells that produce myelin sheaths that insulate axons of neurons, 
enabling saltatory conduction between the Nodes of Ranvier for rapid propogation of action 
potential. These cells are targets of severe developmental diseases such as Pelizaeus- 
Merzbacher disease, and demyelinating diseases such as multiple sclerosis and Charcot-
Marie-Tooth (Bramow et al., 2010, Garbern, 2007, Sargiannidou et al., 2009). Dysfunctional 
oligodendrocytes in these diseases lead to disruptions in axonal transport. In spinal cord 
injury, demyelination of nerve fibres attributes to functional loss of neurons. So, myelin 
formation and insulation of neurons is crucial to restore functional network. Hence, it  is 
important to source for pure poulation of glial (oligodendrocyte precursor) cells that can 
restore function of neurons by remyelination. A few reports and studies from Geron trial 
have shown the feasibility of using functional OPCs or neurotrophin expressing GRPs from 
directed differentiation of hESCs and their therapeutic potential at early time points after 
spinal cord injury (Keirstead et al., 2005, Cao et al., 2005).  
Oligodendrocytes undergo multiple stages of differentiation, from oligodendrocyte 
progenitors, to pro-oligodendrocytes, to non-myelinating oligodendrocytes, and finally 
myelinating oligodendrocytes (Reviewed in Miller, 2000). A protocol by Hu et al. 2009 
provides an excellent example of the procedure for obtaining oligodendrocyte progenitors. 
Briefly, hESC-derived neural progenitors are treated with RA and Shh for patterning into 
the ventral spinal progenitors, followed by FGF2 for inhibition of differentiation into 
motoneurons. Oligodendrocyte progenitors were induced with the addition of factors 
promoting for survival and proliferation of oligodendrocytes – transferrin, progesterone, 
sodium selenite, putrescine, triiodothyronine (T3), neurotrophin 3 (NT3), platelet-derived 
growth factor (PDGF), cyclic adenosine-monophosphate (cAMP), insulin growth factor-1 
(IGF-1) and biotin. Other factors shown to promote oligodendrocyte differentiation of hESCs 
include hepatocyte growth factor (Hu et al., 2009) and extracellular matrix protein 
vitronectin (Gil et al., 2009). Oligodendrocytes have also been shown to be derived from iPS 
cells (Czepiel et al., 2011). 
3. iPSC technology and implications for neurodegenerative diseases  
Neurological diseases are conditions that affect the central and peripheral nervous 
system.  At present pharmacological interventions for many neurological diseases, 
especially the degenerative conditions, are limited and predominantly restricted to 
alleviation of symptoms. Finding drugs for treatment of neurological disorders represents 
one of the critical goals of medical research today. The recent discovery of iPSC 
technology (Takahashi and Yamanaka, 2006) opens the possibility to generate patient 
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specific models of human disease. The generation of patient specific cells using iPSC 
technology will be a powerful resource for both cell therapy and drug screening (Fig2). 
iPSC is particulary important for neurological diseases as there are limited cellular models 
of the nervous system. 
3.1 X-linked diseases 
A disproportionately large number of disease conditions have been associated with the X 
chromosome because the phenotypic consequence of a recessive mutation is revealed 
directly in males for any gene that has no active counterpart on the Y chromosome. Thus, 
although the X chromosome contains only 4% of all human genes, almost 10% of diseases 
with a mendelian pattern of inheritance have been assigned to the X chromosome (307 out of 
3,199). 168 X-link diseases have been explained by mutations in 113 X-linked genes(Ross et 
al., 2005).  
While males carry a single X chromosome, females have two and hence two copies of each 
gene. Yet, as one of their X chromosomes is inactive in each cell, females also have only one 
working X chromosome in each cell. Thus, females havea mosaic of cells that express either 
the paternal X allele or the maternal X allele. This cellular mosaicism gives females a big 
advantage over males in the context of X-linked diseases. When an X-linked gene is 
mutated, the normal cells can partly compensate for the cells that express the mutant allele 
as a result from cell elimination or by functional compensation (Migeon, 2007).  In males, on 
the other hand, all cells express the mutant gene and therefore usually show much more 
severe symptoms.  
Because the process that inactivates X chromosomes is random with respect to parental 
origin of the X, usually half of the female cells contain a working X chromosome from the 
father while the other half contain a working X chromosome from the mother. By 
reprogramming fibroblasts from female with X-linked disease one can generate both the 
perfect pair of control (expressing the normal allele) and experimental (expressing the 
mutant allele) cell types for investigation of the disease phenotype (see schematic Fig. 3). 
These isogenic control and mutant iPS-derived neurons represent a promising source for 
modelling X-linked diseases.  
3.2 Rett syndrome (RTT) 
RTT is one of the most common causes for mental retardation in females, affecting 1 in 10000 
live female births. It was first reported in 1966 by the neurophysiologist Dr. Andreas Rett 
(Rett, 1966). The large majority of RTT cases are caused by sporadic or from germline 
mutations within the coding sequence of the X-linked methyl CpG binding protein 2 
(MeCP2) gene (Amir et al., 1999) and therefore the mutation cannot be detected by simple 
screening of the parents. Females with classic RTT appear normal from birth until 6–18 
months of age, but then they fail to acquire new milestones and enter a period of regression 
during which motor and language skills are lost. These females show a large diversity of 
symptoms, that appear progressively (reviewed in Chahrour and Zoghbi, 2007) until they 
reach a plateau, suggesting that the condition does not involve progressive 
neurodegeneration (Sun and Wu, 2006). The postnatal onset of symptoms might be 
explained by the increase in MeCP2 levels in cortical neurons throughout normal 
development (Akbarian et al., 2001, Balmer et al., 2003, Jung et al., 2003).  
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Fig. 2. The potential of iPSCs technology. Cell sample can be easily obtained from patients 
and cultured in vitro. These cells can then be reprogrammed into iPSCs and further be 
differentiated into the afflicted cells. Cellular phenotype is assessed by measuring cell 
properties (i.e. neural morphology, maturation of synapses, cell survival under stress, etc). 
Once a distinct disease related phenotype is identified, drug screening platform can be 
developed to test their potential to reverse these  phenotypes (in this example, component 
‘c’ is a potential candidate (see Fig. 3) and can be used for further tests in vivo). Another 
usage for this technology is cell therapy - transplantation of the cells back to the patient.   
 
 
Fig. 3. In vitro disease modeling for X-linked diseases. Schematic explaining reprogramming 
of mosaic cell population from a female with X-linked disease, such as RTT, both iPSC 
clones expressing the mutant allele (Xamut Xiwt) and iPSC clones expressing the wild-type 
(Xawt Ximut)  can be expanded and further differentiated into the afflicted cells (i.e. neurons). 
The wild type neurons, can be used as a perfect control for the mutant neurons for further 
studies, such as screening of molecules that might potentially reverse the symptoms. 
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Although MeCP2 is expressed in a large variety of cells, the most afflicted cells in RTT are 
neurons. In agreement, a specific knockout in the central nervous system revealed the same 
spectrum of symptoms as the full mouse knockout. Several specific neurons were studied in 
the context of RTT. For example, pyramidal glutaminergic neurons, which show obvious 
morphological differences when they express the mutation (see Fig. 3), can account for the 
mental retardation seen in RTT; dopaminergic  neurons can account for the motor function; 
neurons in the Amygdala can affect learning and memory; and hypothalamus neurons can 
affect feeding, aggression and stress.  
In females, the major source for phenotypic variability is the pattern of X chromosome 
inactivation (XCI) (Bourdon et al., 2001). Females with classical RTT are usually a balanced 
mosaic with regard to MeCP2 expression (Adler et al., 1995), whereby half of their cells 
express the wild-type MeCP2 allele and the other half express the mutant MeCP2 allele 
(Shahbazian et al., 2002). However, sometimes, by chance, the XCI pattern favors expression 
of the wild-type allele. Such ‘lucky’ females might show milder symptoms and even to be 
asymptomatic(Sirianni et al., 1998). Another source for phenotypic variability is the type of 
mutation in the MeCP2 gene. Over 300 different mutations in the gene MeCP2 were 
identified, which are the major source of the phenotypic variability in males with RTT. Thus 
generation of iPSCs from multiple patients might shed more light on the correlation 
between mutation type and symptoms as well as the function of different domains in 
MeCP2 protein. In addition, there are important implications for drug screening, as some 
drugs might treat patients with certain mutations but not others. For example, 
aminoglycosides antibiotics, such as gentamicin, can increase wild type MeCP2 expression 
levels in affected neurons by skipping a premature stop codon by bind to the 16S rRNA, 
impairing ribosomal proofreading (Kellermayer, 2006, Marchetto et al., 2010). Thus, disease 
modeling for multiple patients will allow us to tailor specific drugs for each patient.  
Initially, RTT was thought to be a neurodegenerative disease, however, the decrease in 
axondendritic arborization and impaired development of dendrites (Fig. 4) suggest that RTT 
is a disorder featuring an arrest in neuronal development (Hagberg, 1985, Belichenko et al., 
1994, Armstrong, 1992, Armstrong, 2001). Furthermore, no obvious cell death is seen in RTT, 
and this therefore begs the question of whether restoring MeCP2 expression would restore 
normal neuronal function and reverse the resulting disease phenotypes. In a seminal work, 
Guy et al (2007) provide evidence supporting the feasibility of disease reversibility in mouse 
models of RTT (Guy et al., 2007). They created a mouse in which endogenous MeCP2 is 
silenced by insertion of a Lox-Stop cassette and can be conditionally activated through Cre-
mediated deletion of the cassette. The MeCP2 lox-Stop allele behaved as a null mutation, 
and its activation was controlled by a tamoxifen-inducible Cre transgene. Gradual tamoxifen 
injection reversed the late-onset neurological phenotype of adult  MeCP2-lox-Stop/+; cre 
heterozygotes, indicating that MeCP2-deficient neurons are not permanently damaged, 
since MeCP2 activation leads to robust abrogation of advanced neurological defects in both 
young and adult animals. This work establish that consequences of MeCP2 loss of function 
are reversible, and suggest that the neurological defects in RTT, and other MeCP2 disorders, 
are not impervious to therapeutic possibilities. Indeed, several molecules, have delayed the 
onset of RTT-like symptoms in animal models, and enhanced survival rates (Chang et al., 
2006, Ogier et al., 2007). Potential molecules for treatment of RTT are BDNF, IGF-1 and NGF. 
A molecule with promise in RTT therapy is BDNF. There are phenotypic similarities 
between MeCP2- and BDNF-null mice, including a reduction in brain weight and hindlimb 
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clasping. Over expression of BDNF in  MeCP2-null mouse brains delayed the onset of RTT-
like symptoms, and enhanced survival rates (Chang et al., 2006, Ogier et al., 2007). More 
specifically, BDNF overexpression rescued the hypoactivity in wheel running exhibited by 
MeCP2 knockout mouse, and the low frequency of action potential firing observed in their 
cortical neurons (Chang et al., 2006); and treatment of MeCP2 null mice with AMPAkines 
(which increases BDNF mRNA and protein levels) rescued the irregular respiratory patterns 
exhibited by MeCP2. However, the therapeutic utility of BDNF is hampered by its poor 
efficiency at crossing the blood–brain barrier. Nevertheless, a therapeutic intervention in 
humans might thus arise from identifying an agent similarly capable of stimulating synaptic 
maturation.  
An in vitro disease modeling for RTT was established by Marchetto et al (2010). In this study 
they reprogrammed fibroblasts from RTT patients into iPSCs, and further differentiated 
them into neurons. When analyzed, these neurons showed lower synaptic density, simpler 
morphology with less branching and smaller cell body. Furthermore, by using 
electrophysiological methods they showed that RTT neurons have a significant decrease in 
frequency and amplitude. This is in agreement with studies on RTT mice models and on 
postmortem brain tissues from patients. This RTT disease model was used to screen 
molecules, such as IGF-1. Like BDNF, IGF-1 is widely expressed in the CNS during normal 
development (D'Ercole et al., 1996), strongly promotes neuronal cell survival and synaptic 
connections. Indeed, IGF-1 treatment leads to a partial rescue of RTT (Tropea et al., 2009).  
In their study, Marchetto et al (2010) investigated the use of IGF1 and gentamicin in iPSC-
derived neurons carrying a MeCP2 mutation. While IGF1 treatment increased synapse 
number in some clones, it stimulated glutamatergic RTT neurons above normal levels. 
Gentamicin was used to rescue neurons derived from iPSCs carrying a nonsense MeCP2 
mutation by increasing full-length MeCP2 levels in RTT neurons, rescuing glutamatergic 
synapses. Thus, this in vitro disease model can be used to screen therapeutic candidate 
molecules.   
 
 
Fig. 4. Schematic representation of drug screening for pyramidal neurons carrying MeCP2 
mutation. In RTT, the cell body is small and there is reduced dendritic branching 
(Armstrong 1995), fewer synapses, and reduced spine density compared to the control. 
These morphological differences can be an indicator for drug screening. In this example, 
component ‘C’ reverses the impaired morphology of the RTT neurons and therefore can be 
further studied in RTT animal models as a potential drug to reverse the RTT symptoms.    
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3.3 Familial dysautonomia 
Familial dysautonomia (FD), also known as Riley–Day syndrome or HSAN-III is a 
neurodevelopmental disorder, caused by a mutation in the I-k-B kinase complex-associated 
protein (IKBKAP) gene on chromosome 9. This condition is affects 1 in 3,700 Eastern 
European Jewish ancestry (Ashkenazi Jews), but rare in the general population. The disease 
was first reported by Conrad Milton Riley and Richard Lawrence. It is a fatal autosomal 
recessive disease characterized by the degeneration of sensory and autonomic neurons 
(Slaugenhaupt et al., 2001, Axelrod et al., 2002), resulting in variable symptoms including: 
insensitivity to pain, inability to produce tears, poor growth, and labile blood pressure 
(episodic hypertension and postural hypotension). Future parents can be screened for the 
mutation and if both parents are shown to be carriers by genetic testing, there is a 25% 
chance that the child will produce FD. The point mutation in the IKBKAP gene results in a 
tissue-specific splicing defect with various levels of exon 20 skipping and reduced levels of 
normal IKBAP protein (Slaugenhaupt et al., 2001, Anderson et al., 2001). The ratio between 
the normal and mutant transcripts affects the severity of the disease. 
An iPSC-based model for FD was established by Lee et al (Lee et al., 2009). FD-iPSC-derived 
neural crest showed reduced migration as well as decreased rate of neurogenesis. 
Furthermore, when they screened the afflicted cells with candidate drugs, they found that 
kinetin resulted in a marked reduction of the mutant IKBKAP splice form, associated with 
an increase in normal IKBKAP levels. This treatment increased the percentage of 
differentiating neurons but it did not affect the migration potential of the neural crest. Thus 
FD-iPSC model is an example of gaining insight about early progession of a neuro-
developmental disease. 
3.4 Parkinson’s disease 
Parkinson’s disease (PD) is one of the most widely studied neurodegenerative disease 
caused by the progressive degeneration of midbrain dopaminergic neurons. Although the 
aetiology of PD remains enigmatic, partially attributed to complex environmental factors, 
and mutations in several genes (LRRK-2, Parkin, DJ-1, PINK1, ATP13A2, alpha-synuclein, 
GBA) have been found to give rise to PD-like pathogenesis. However, these genetic factors 
contribute to only a small fraction of PD cases, impeding significant progress in 
understanding PD pathogenesis completely. Moreover, it was found in PD patients who had 
received neuronal grafts through transplantation that the cells which were previously young 
and healthy developed α–synuclein and ubiquitin-positive Lewy bodies after more than a 
decade. This led to the proposal of several mechanisms such as inflammation, oxidative 
stress, excitotoxicity and growth-factor deprivation that may have substantial impact on the 
propagation of PD (Brundin et al., 2008). Thus, it would be necessary to re-examine the 
disease pathology by mimicking characteristics of the disease under these varied conditions 
or in combination with known genetic defects since the benefits of cell transplantation in PD 
trials is still uncertain. This objective may soon be achievable as Soldner et al (2009) 
demonstrated that iPSCs could be derived from patients with idiopathic PD. Furthermore, 
the iPSCs could be directed to differentiate into dopaminergic neurons through EB 
formation in the presence of FGF2, FGF8 and Shh. Coupled with the possibility of deriving 
large-scale functional dopaminergic neurons; via the generation of homogenous spherical 
neural masses (Cho et al., 2008), the ultimate goal of creating patient-specific neuronal cells 
for transplantation therapy may soon be in the pipeline. It is reassuring to note that neurons 
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reprogrammed from mouse fibroblasts were able to integrate functionally into the fetal 
brain and improve the locomotor behavior in at least a rat model of PD upon 
transplantation into the adult brain (Wernig et al., 2008). However, whether these 
transplanted cells will succumb to the same fate in the long-term as observed in the post-
mortem human PD trails remains to be investigated. 
3.5 Huntington’s disease 
Huntington’s disease (HD) is caused by CAG repeats in the N-terminus of the gene 
encoding Huntingtin protein. Like Lewy proteins in Parkinson’s disease patients,  the 
expression of aberrant polyglutamine-containing molecules in HD leads to massive loss of 
medium spiny neurons in the striatum and neurons in the cortex as the disease progresses. 
Despite substantial efforts invested in various cellular and animal models to understand the 
disease, the mechanisms implicated in the selective cell death of neurons remains unclear 
and there is no cure at present. One major hurdle is the lack of appropriate human samples 
carrying the genetic mutation for HD which would offer the most ideal system for 
investigating the process of neurodegeneration. With the advent of iPSC technology, HD-
specific iPSCs were generated (Park et al., 2008). Thereafter, HD specific NSCs 
(nestin+/PAX6+/SOX1+/OCT4-) were obtained and these were subjected to differentiation 
conditions combining morhogens (SHH and DKK1) and neurotrophins (BDNF) to induce 
neurons of the striatal lineages (Zhang et al.). Importantly, these neurons contained the 
same CAG expansion as the mutation in the HD patient in which the iPSC line was 
established. Thus, a valuable resource is now available to search for drugs that can reduce 
the toxicity of polyglutamine. 
3.6 Amyotrophic lateral sclerosis 
Another seminal study to interrogate a deliberating disease, arising from the progressive 
degeneration of motor neurons of the spinal cord using the iPSC technology is amyotrophic 
lateral sclerosis (ALS) (Dimos et al., 2008). In this landmark study, skin fibroblasts produced 
directly from an 82-year-old elderly woman patient, diagnosed clinically with ALS and a 
SOD1 mutation were reprogrammed successfully into the pluripotent state. These patient-
specific iPSCs showed strong alkaline phosphatase activity and exhibited markers (SSEA-3, 
SSEA-4, TRA1-60 and TRA1-81) and a transcriptional profile (REX1, FOXD3, TERT, NANOG 
and CRIPTO) that are comparable to pluripotent hESCs. Furthermore, these cells could form 
EBs and were capable of differentiating into cells of the germ layers. Most importantly the 
iPSCs were directed specifically towards both motor neurons and glia fates, enabling further 
exploration of either a cell autonomous (such as the amount of SOD1 in motor neurons) or 
non-cell-autonomous (such as the role of neighboring astrocytes, microglia and 
oligodendrocytes) function of the disease as implicated in rodent models (Boillee et al., 2006, 
Yamanaka et al., 2008). Thus, the iPSC technology essentially reversed the patient’s history 
to allow the onset and progression of ALS to be captured in culture for drawing mechanistic 
insights.  
In addition to ALS, Park and co-workers (Park et al., 2008) managed to single-handedly 
generate reprogrammed cells from patients with a range of genetic diseases that were either 
Mendelian or complex in inheritance. The diseases in which iPSCs were derived include: 
adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), 
Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne 
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(DMD) and Becker muscular dystrophy (BMD), Parkinson disease, Huntington disease, 
juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21 and the 
carrier state of Lesch-Nyhan syndrome. Similar to the set of assays used in the 
characterization of the ALS iPSCs, these disease-associated iPSC lines were all confirmed to 
be pluripotent and capable of multi-lineage differentiation. Moreover, these human iPSCs 
produced teratomas in immunodeficient Rag2−/−γC−/− mice, the golden standard for 
testing pluripotency. Taken together, these efforts undoubtedly demonstrated the feasibility 
of the iPSC technology to reprogram somatic cells from a variety of diseased patients. And 
in the process, provided valuable source of material that pave the way for unraveling 
disease mechanisms and customized cellular therapies tailored for the individual.     
4. Conclusion 
Research on hESCs has allowed the development of specific protocols for generation of 
neural progenitors and differentiated neural lineages. These protocols can now be applied to 
iPSCs to enable the generation of specific neurons, astrocytes and oligodendrocytes. The 
availability of samples from relevant donors carrying different mutations will also facilitate 
modelling of neuronal diseases by reprogramming somatic cells. A ‘mutation library’ for a 
particular disease can then serve as a platform for the tailoring of specific drugs for specific 
patients. Furthermore, disease modelling from multiple patients might provide additional 
insights on the pathogenesis of the disease; particularly RTT in which specific mutations are 
associated with variable severity in clinical symptoms. Another advantage in 
reprogramming is that the clinical history of every donor is known. This will allow us to 
model diseases in which the genetic component is not known such as Alzheimer and 
Parkinson’s.  Thus the use of iPSCs technology will herald a new era in the study of 
neurological diseases. 
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